Drug Type AAV based gene therapy |
Synonyms FT 001, FT001 |
Target |
Mechanism BET inhibitors(Bromodomain and extra terminal domain protein inhibitors), RPE65 gene transference |
Therapeutic Areas |
Inactive Indication- |
Originator Organization Frontera Therapeutics, Inc.Startup |
Active Organization Frontera Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Start Date12 Dec 2022 |
Sponsor / Collaborator Frontera Therapeutics, Inc.Startup [+2] |
Start Date30 Nov 2022 |
Sponsor / Collaborator Frontera Therapeutics, Inc.Startup |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Biallelic RPE65 mutation associated retinal dystrophy | Phase 2 | CN | Frontera Therapeutics, Inc.Startup | 30 Nov 2022 |
Amaurosis Congenita of Leber, Type 2 | Phase 2 | CN | Frontera Therapeutics, Inc.Startup | - |
Retinal Diseases | Phase 1 | US | Frontera Therapeutics, Inc.Startup | 19 Jul 2022 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |